The TB-500 fragment
The seven-amino-acid fragment shares a region with the whole protein. Most of the research belongs to the whole protein.
The fragment’s identity
TB-500 is Ac-LKKTETQ, a synthetic, acetylated 7-amino-acid fragment corresponding to residues 17-23 of the 43-amino-acid protein thymosin beta-4. That region contains the actin-binding motif. The review of thymosin beta-4 biology explains why the region interests people studying tissue repair.
Shortening molecule and name together has an obvious appeal. The difficulty is that a shared region establishes a relationship, while the behaviour of the detached fragment still needs its own experiments. The 2026 review describes a field with scarce rigorous human safety data. No completed controlled human trial establishes the TB-500 fragment's benefits or safety.
The volunteer study
In the randomised 2010 trial, 40 healthy volunteers received intravenous synthetic full-length thymosin beta-4 or placebo. Across the tested cohorts, treatment was well tolerated; adverse events were infrequent and mild-to-moderate, and no dose-limiting toxicities occurred. This was a Phase 1 safety study.
The tested substance was full-length thymosin beta-4. The study did not test TB-500 or a blend.
I credit the volunteer finding to the protein that was tested. It describes tolerability of a specified protein in healthy volunteers. Extending it to the fragment would require another experiment, and extending it to injury recovery would require an efficacy endpoint as well.
Actin biology
Actin supplies part of a cell's internal scaffolding. A structural study of thymosin beta-4 bound to actin established how the protein holds an actin monomer in a 1:1 complex, capping both ends and preventing it joining a filament. That reserve matters when a cell reorganises itself to move.
The 2012 review connects full-length thymosin beta-4 with migration, blood-vessel growth and reduced scar-forming cells in injury models. The physical work of movement absorbs me: a cell has to rearrange its own structure to change position. The isolated TB-500 fragment's ability to reproduce the full collection of effects remains unsettled.
The rat stroke result
The 2014 dose-response experiment in rats with induced stroke is an awkward result for a simple escalation story. Full-length thymosin beta-4 improved neurological function at study doses of 2 and 12 mg/kg; 18 mg/kg produced no significant benefit. Benefit at the effective study doses was measurable from day 14 through day 56.
These were rat experiments with the parent protein. That uneven result spoils the appeal of a simple escalation rule for me. It establishes no human regimen.
TB-500 safety
Accounts of less stiffness, easier movement and quicker recovery circulate alongside reports of fatigue, local injection reactions, lightheadedness and nausea. Those accounts are anecdotal and do not constitute clinical evidence for the fragment. They also give no reliable estimate of how often any outcome occurs.
TB-500 is unapproved and WADA-prohibited. The sports-medicine review warns about uncertain human safety and potential serious harm. Pro-angiogenic and cell-migration activity raises theoretical cancer concerns; human fragment studies have not settled them. Research-product identity and purity add another uncertainty, while pregnancy, breastfeeding and childhood safety data are absent. The same fragment appears in Wolverine, GLOW and KLOW, carrying its identification problem with it.